Travere's sparsentan misses primary eGFR endpoint in Phase 3 FSGS study; proteinuria trends favorable

Travere Therapeutics, Inc.

eGFR total slope difference 0.3 mL/min/1.73m2/yr favoring sparsentan (p=0.7491), not statistically significant.
eGFR chronic slope difference 0.9 mL/min/1.73m2/yr (p=0.4203), also not significant.
Proteinuria reduced 50% with sparsentan vs 32% with irbesartan at week 108; FPRE 38% vs 23%.
Company plans to engage FDA and EMA to explore potential path for regulatory submission.
Sparsentan well-tolerated with safety profile comparable to irbesartan through 108 weeks.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.